Are you Dr. Zane?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1701 Divisadero St., 3rd Floor
San Francisco, CA 94143Phone+1 415-353-7800Fax+1 415-353-7870
Summary
- Dr. Lee Zane, MD is a board certified dermatologist in San Francisco, California. He is currently licensed to practice medicine in California.
Education & Training
University of California (San Francisco)Residency, Dermatology, 2000 - 2003
Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1999 - 2000
Stanford University School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2000 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis Start of enrollment: 2008 Sep 01
- Cumulative Irritation Test Start of enrollment: 2008 Oct 01
- Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections Start of enrollment: 2009 Nov 05
- Join now to see all
Publications & Presentations
PubMed
- 104 citationsEfficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized pha...Boni E. Elewski, Raza Aly, Sheryl L. Baldwin, Remigio F. González Soto, Phoebe Rich
Journal of the American Academy of Dermatology. 2015-07-01 - 47 citationsCrisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.Dedee F. Murrell, Kurt Gebauer, Lynda Spelman, Lee T Zane
Journal of Drugs in Dermatology. 2015-10-01 - 37 citationsEarly relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitorGil Yosipovitch, Linda Stein Gold, Mark Lebwohl, Jonathan I. Silverberg, Anna M. Tallman
Acta Dermato-Venereologica. 2018-04-27
Press Mentions
Anacor Pharmaceuticals Announces Top-Line Results from Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients with Mild-to-Moderate Atopic DermatitisFebruary 23rd, 2016
Study Lets Teens Sound off on Acne TherapiesAugust 18th, 2008
Professional Memberships
- Fellow
